 |
Caution: Federal law prohibits dispensing without prescription.
Each mL contains:
Antipyrine ............................................ 54.0 mg
Benzocaine ........................................... 14.0 mg
Glycerin dehydrated q.s. to ..................... 1.0 mL
(contains not more than 0.6% moisture)
(also contains oxyquinoline sulfate)
TOPICAL DECONGESTANT AND ANALGESIC
Auralgan is an otic solution containing antipyrine, benzocaine, and dehydrated glycerin. The solution congeals at 0° C (32° F), but returns to normal consistency, unchanged, at room temperature.
The structures of the components are:
|
|
antipyrine benzocaine glycerin
Auralgan combines the hygroscopic property of dehydrated glycerin with the analgesic action of antipyrine and benzocaine to relieve pressure, reduce inflammation and congestion, and alleviate pain and discomfort in acute otitis media.
Auralgan does not blanch the tympanic membrane or mask the landmarks and, therefore, does not distort the otoscopic picture.
ACUTE OTITIS MEDIA OF VARIOUS ETIOLOGIES
-- prompt relief of pain and reduction of inflammation in the congestive and serous stages
-- adjuvant therapy during systemic antibiotic administration for resolution of the infection
Because of the close anatomical relationship of the eustachian tube to the nasal cavity, otitis media is a frequent problem, especially in children in whom the tube is shorter, wider, and more horizontal than in adults.
REMOVAL OF CERUMEN
--facilitates the removal of excessive or impacted cerumen
Hypersensitivity to any of the components or substances related to them.
Perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal.
Discontinue promptly if sensitization or irritation occurs.
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
No long-term studies in animals or humans have been conducted
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with Auralgan. It is also not known whether Auralgan can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. Auralgan should be given to a pregnant woman only if clearly needed.
NURSING MOTHERS
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Auralgan is administered to a nursing woman.
Instill Auralgan permitting the solution to run along the wall of the canal until it is filled. Avoid touching the ear with dropper. Then moisten a cotton pledget with Auralgan and insert into meatus. Repeat every one to two hours until pain and congestion are relieved.
REMOVAL OF CERUMEN
| Before: | Instill Auralgan three times daily for two or three days to help detach cerumen from wall of canal and facilitate removal. |
| After: | Auralgan is useful for drying out the canal or relieving discomfort. |
Before and after removal of cerumen, a cotton pledget moistened with Auralgan should be inserted into the meatus following instillation.
Note: Do not rinse dropper after use.
Replace dropper in bottle after each use. Hold dropper assembly by screw cap and, without compressing the rubber bulb, insert into drug container and screw down tightly.
Protect the solution from light and heat, and do not use if it is brown or contains a precipitate.
DISCARD THIS PRODUCT SIX MONTHS AFTER DROPPER IS FIRST PLACED IN THE DRUG SOLUTION.
Auralgan® Otic Solution, in package containing 10 mL bottle with separate dropper-screw cap attachment (NDC 0046-1000-10).
Manufactured by:
Ayerst Laboratories Inc.
A Wyeth-Ayerst Company
Philadelphia, PA 19101
CI 4660-2 Revised December 3, 1996